The U.S. is expected to maintain the largest share of the market at 65.6 percent. U.S. market revenue is forecasted to increase at a slightly lower CAGR of 3.5 percent from $1.39 billion to $1.78 billion.
The market includes allografts, bone morphogenetic proteins, demineralized bone matrices, synthetic bone substitutes and more.
More Articles on Devices:
Kiva Device for Spinal Fractures Cleared by FDA
Device Companies — 7 Key Notes — Stryker, Orthofix & More
4 Recent Spine & Orthopedic Device Company Expansions
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
